SURGEON TIAN WEI came across one of the most challenging orthopaedic surgeries in his 30-year career in 2015.
A 43-year-old patient had complained of progressive numbness in the limbs on his right side for 14 months, caused by a deformity in his upper cervical vertebrae.
The patient was in dire need of surgery to implant a screw to help support his neck bone, but the operation was risky. Any minor mistake could lead to paralysis or a life-threatening haemorrhage. Many hospitals were unwilling to treat him.
But Tian, who also is president of Beijing Jishuitan Hospital, decided to do the surgery – with a little help from another “surgeon”.
Ads By AdAsia
You can close Ad in 2 s
The operation was completed in an hour with help of Phecda, a surgical robot with a three-dimensional high-definition visual system that can “see” the internal orthopaedic structure and a “hand” that can guide medical tools to the proper location within 0.8 millimetre.
Developed by Beijing Tinavi Medical Technology Co with the help of Jishuitan Hospital, Phecda is part of the broad effort by Chinese companies to out-compete foreign rivals just as the country’s use of medical robots is set to take off, motivated in part by an ageing population.
Medical robots are highlighted in the country’s “Made in China 2025” strategy, which was designed to promote high-end manufacturing.
“That was the world’s first robot-assisted surgery on upper cervical vertebrae,” Tian said, describing the 2015 clinical trial. “Phecda is more precise than foreign products and its cost is lower.”
Phecda, which is the third-generation surgery robot developed by Tinavi, is ready to be commercialised this year after obtaining approval from China’s Food and Drug Administration last July.
Chinese medical-robot makers like Tinavi are working hard to outshine foreign companies in both price and quality as they benefit from ample demand, strong policy support and manufacturing prowess, company executives and experts have said.
By 2050, more than 400 million Chinese will be over 60 years old, accounting for more than 30 per cent of the population, up from about 16.1 per cent in 2015, official data show.
“The growing number of senior citizens will offer a sizeable quantity of clinical cases, and enterprises can leverage a huge database to accelerate R&D,” or research and development, said Zhang Songgen, chairman of Tinavi.
Last April, China unveiled its plan to sell more than 30 billion yuan (Bt154 billion) worth of domestic service robots by 2020. Medical robots are an important part of the ambitious goal, Zhang said.
In 2016, China’s medical-robotics market was valued at 791 million yuan, up 34.4 per cent from |2015, according to a report by the Beijing-based research company GCiS.
“From surgery, rehabilitation, drug delivery to home care, robots are set to transform China’s healthcare industry, ” GCiS predicted.
In addition to Tinavi, whose robots have completed around 2,000 surgeries since 2010, there are many new players.
One of them is Chongqing Jinshan Science and Technology. The company started as a maker |of capsule endoscopes, or pill-sized cameras that record images of the digestive tract. Its products, approved by US medical authorities in 2008, are available in more than 60 countries.
Jinshan has become partners with the well-regarded Harbin Institute of Technology on China’s first minimally invasive surgical robot for thoracic and celiac diseases. It is scheduled to go into clinical testing soon.
“China’s medical-robot sector is still in its infancy. But home-grown enterprises and universities are more united than ever in the R&D of core technologies. They are narrowing the gap with foreign leaders such as US company Intuitive Surgical’s Da Vinci surgery robot,” said Guo Xuan, deputy director of Beijing-based Yizhuang Smart Robotics Industry Research Institute. Strong policy support has helped, Guo said.
Yu Shaoyu, a government official in charge of attracting high-tech enterprises to Wuxi, Jiangsu province, said: “We have set up an industry fund to encourage medical-robot makers, and will offer them a slate of preferential policies, including rent rebates and help in intellectual-property applications.”
Public hospitals are also encouraged to play an active part. China PLA Navy General Hospital has developed the neurosurgical robot Remebot through a partnership with Beijing University of Aeronautics and Astronautics.
“It is very important to win support from hospitals because they are the buyers of most medical robots and know exactly what is needed,” said Luo Jun, chief executive of the International Robotics and Intelligent Equipment Industry Alliance.
The field is so promising that Midea Group, a major Chinese home-appliances maker, also has joined in. It set up a joint venture in 2015 with Yaskawa Electric Corp, a Japanese robot maker, to develop nursing-care and rehabilitation robots. “Our manufacturing prowess in consumer electronics will help to rapidly bring rehabilitation robots to people’s homes,” said Zhen Shaoqiang, general manager of Midea’s robotics business.
A 43-year-old patient had complained of progressive numbness in the limbs on his right side for 14 months, caused by a deformity in his upper cervical vertebrae.
The patient was in dire need of surgery to implant a screw to help support his neck bone, but the operation was risky. Any minor mistake could lead to paralysis or a life-threatening haemorrhage. Many hospitals were unwilling to treat him.
But Tian, who also is president of Beijing Jishuitan Hospital, decided to do the surgery – with a little help from another “surgeon”.
Ads By AdAsia
You can close Ad in 2 s
The operation was completed in an hour with help of Phecda, a surgical robot with a three-dimensional high-definition visual system that can “see” the internal orthopaedic structure and a “hand” that can guide medical tools to the proper location within 0.8 millimetre.
Developed by Beijing Tinavi Medical Technology Co with the help of Jishuitan Hospital, Phecda is part of the broad effort by Chinese companies to out-compete foreign rivals just as the country’s use of medical robots is set to take off, motivated in part by an ageing population.
Medical robots are highlighted in the country’s “Made in China 2025” strategy, which was designed to promote high-end manufacturing.
“That was the world’s first robot-assisted surgery on upper cervical vertebrae,” Tian said, describing the 2015 clinical trial. “Phecda is more precise than foreign products and its cost is lower.”
Phecda, which is the third-generation surgery robot developed by Tinavi, is ready to be commercialised this year after obtaining approval from China’s Food and Drug Administration last July.
Chinese medical-robot makers like Tinavi are working hard to outshine foreign companies in both price and quality as they benefit from ample demand, strong policy support and manufacturing prowess, company executives and experts have said.
By 2050, more than 400 million Chinese will be over 60 years old, accounting for more than 30 per cent of the population, up from about 16.1 per cent in 2015, official data show.
“The growing number of senior citizens will offer a sizeable quantity of clinical cases, and enterprises can leverage a huge database to accelerate R&D,” or research and development, said Zhang Songgen, chairman of Tinavi.
Last April, China unveiled its plan to sell more than 30 billion yuan (Bt154 billion) worth of domestic service robots by 2020. Medical robots are an important part of the ambitious goal, Zhang said.
In 2016, China’s medical-robotics market was valued at 791 million yuan, up 34.4 per cent from |2015, according to a report by the Beijing-based research company GCiS.
“From surgery, rehabilitation, drug delivery to home care, robots are set to transform China’s healthcare industry, ” GCiS predicted.
In addition to Tinavi, whose robots have completed around 2,000 surgeries since 2010, there are many new players.
One of them is Chongqing Jinshan Science and Technology. The company started as a maker |of capsule endoscopes, or pill-sized cameras that record images of the digestive tract. Its products, approved by US medical authorities in 2008, are available in more than 60 countries.
Jinshan has become partners with the well-regarded Harbin Institute of Technology on China’s first minimally invasive surgical robot for thoracic and celiac diseases. It is scheduled to go into clinical testing soon.
“China’s medical-robot sector is still in its infancy. But home-grown enterprises and universities are more united than ever in the R&D of core technologies. They are narrowing the gap with foreign leaders such as US company Intuitive Surgical’s Da Vinci surgery robot,” said Guo Xuan, deputy director of Beijing-based Yizhuang Smart Robotics Industry Research Institute. Strong policy support has helped, Guo said.
Yu Shaoyu, a government official in charge of attracting high-tech enterprises to Wuxi, Jiangsu province, said: “We have set up an industry fund to encourage medical-robot makers, and will offer them a slate of preferential policies, including rent rebates and help in intellectual-property applications.”
Public hospitals are also encouraged to play an active part. China PLA Navy General Hospital has developed the neurosurgical robot Remebot through a partnership with Beijing University of Aeronautics and Astronautics.
“It is very important to win support from hospitals because they are the buyers of most medical robots and know exactly what is needed,” said Luo Jun, chief executive of the International Robotics and Intelligent Equipment Industry Alliance.
The field is so promising that Midea Group, a major Chinese home-appliances maker, also has joined in. It set up a joint venture in 2015 with Yaskawa Electric Corp, a Japanese robot maker, to develop nursing-care and rehabilitation robots. “Our manufacturing prowess in consumer electronics will help to rapidly bring rehabilitation robots to people’s homes,” said Zhen Shaoqiang, general manager of Midea’s robotics business.
Resource : http://www.nationmultimedia.com/news/business/corporate/30306283
